期刊文献+

PRAME mRNA和SOX9 mRNA在肺腺癌中的表达及临床意义 被引量:3

Expression of PRAME mRNA and SOX9 mRNA in lung adenocarcinoma and its clinical significance
下载PDF
导出
摘要 目的探讨黑色素瘤特异性抗原(PRAME)mRNA和性别决定基因盒9(SOX9)mRNA在肺腺癌中的表达及临床意义。方法选取2015年2月至2018年4月于该院接受手术治疗的73例肺腺癌患者为研究对象,术中收集肺腺癌癌组织及癌旁正常组织,采用实时荧光定量PCR检测不同组织中PRAME mRNA、SOX9 mRNA的相对表达水平并进行比较;分析肺腺癌患者癌组织PRAME mRNA、SOX9 mRNA表达与临床病理特征的关系;采用Spearman相关分析PRAME mRNA表达与SOX9 mRNA表达的相关性;分析PRAME mRNA、SOX9 mRNA表达与肺腺癌患者预后的关系;采用COX回归模型分析影响肺腺癌患者预后的因素。结果与癌旁正常组织相比,肺腺癌癌组织PRAME mRNA的相对表达水平降低(P<0.05),SOX9 mRNA的相对表达水平升高(P<0.05)。PRAME mRNA、SOX9 mRNA表达与肺腺癌患者性别、年龄、肿瘤大小无关(P>0.05),与病理分级、临床分期、淋巴结转移有关(P<0.05)。Spearman相关分析显示,肺腺癌癌组织PRAME mRNA表达与SOX9 mRNA表达呈负相关(P<0.05)。与预后良好组相比,预后不良组肺腺癌患者PRAME mRNA的相对表达水平降低(P<0.05),SOX9 mRNA的相对表达水平升高(P<0.05)。COX回归模型分析结果显示,PRAME mRNA低表达、SOX9 mRNA高表达、低分化、临床分期Ⅲ期、有淋巴结转移均是影响肺腺癌患者预后的独立危险因素(P<0.05)。结论肺腺癌癌组织中PRAME mRNA、SOX9 mRNA表达异常,且两者呈负相关,可能为肺腺癌的病情及预后评估提供参考依据。 Objective To investigate the expression and clinical significance of preferentially expressed antigen of melanoma(PRAME)mRNA and sex-determining region Y box 9(SOX9)mRNA in lung adenocarcinoma.Methods Totally 73 patients with lung adenocarcinoma who were treated in the hospital from February 2015 to April 2018 were selected as the study objects.The tissues of lung adenocarcinoma and adjacent normal tissues were collected during the operation.The relative expression levels of PRAME mRNA and SOX9 mRNA in different tissues was detected by real-time quantitative PCR,and the relationship between the expression of PRAME mRNA and SOX9 mRNA in the focus tissues of patients with lung adenocarcinoma and the clinicopathological characteristics was analyzed.Spearman correlation was used to analyze the correlation between the expression of PRAME mRNA and SOX9 mRNA.The relationship between the expression of PRAME mRNA and SOX9 mRNA and the prognosis of patients with lung adenocarcinoma was analyzed.Cox regression model was used to analyze the factors affecting the prognosis of patients with lung adenocarcinoma.Results Compared with adjacent normal tissues,the relative expression level of PRAME mRNA in lung adenocarcinoma tissue was lower(P<0.05),and the relative expression level of SOX9 mRNA was higher(P<0.05).The expression of PRAME mRNA and SOX9 mRNA was not correlated with gender,age and tumor size(P>0.05),but correlated with pathological grade,clinical stage and lymph node metastasis(P<0.05).Spearman correlation analysis showed that the expression of PRAME mRNA was negatively correlated with SOX9 mRNA in lung adenocarcinoma(P<0.05).Compared with good prognosis group,the relative expression level of PRAME mRNA was lower and the relative expression level of SOX9 mRNA was higher in poor prognosis group(P<0.05).COX regression model analysis showed that low expression of PRAME mRNA,high expression of SOX9 mRNA,poor differentiation,stageⅢclinical stage and lymph node metastasis were independent risk factors for the prognosis of patients with lung adenocarcinoma(P<0.05).Conclusion The abnormal expression of PRAME mRNA and SOX9 mRNA may be involved in the occurrence and progression of lung adenocarcinoma,and the two are negatively correlated.It may provide a reference for the condition evaluation and prognosis evaluation of lung adenocarcinoma and targeted therapy.
作者 韩文慧 邓慧兰 王辉 何萌萌 HAN Wenhui;DENG Huilan;WANG Hui;He Mengmeng(First Department of Respiration,Qingdao Jiaozhou Central Hospital,Qingdao,Shandong 266300,China)
出处 《国际检验医学杂志》 CAS 2021年第9期1069-1073,共5页 International Journal of Laboratory Medicine
基金 山东省医药卫生科技发展计划(2017WS0149)。
关键词 黑色素瘤特异性抗原 性别决定基因盒9 肺腺癌 临床病理特征 preferentially expressed antigen of melanoma sex-determining region Y box 9 lung adenocarcinoma clinicopathological features
  • 相关文献

参考文献10

二级参考文献64

  • 1Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2015, 10(7): 900-1003.
  • 2Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2015, 10(12): 1675-84.
  • 3Eberhardt WE, MitchelI A, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cance r[J]. J Thorac Oncol, 2015, 10(11): 1515-22.
  • 4Rami-Porta R, Bolejack V, Giroux DJ, et al. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer[J]. J Thorac Oncol, 2014, 9(ll): 1618-24.
  • 5Wittekind C, Compton C, Brierley J, et al. TNM Supplement A Commentary on Uniform Use 4th Ed[M]. Oxford: Wiley- Blackwell, 2012: 6.
  • 6Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ ATS/ERS classification of lung adenocarcinoma: prognostic subgroups andimplications for further revision of staging based on analysis of 514 stage I cases[J]. Mod Pathol, 2011, 24(5): 653-64.
  • 7Tsutani Y, Miyata Y, Nakayama H, et al. Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: a multicenter study[J]. J Thorac Cardiovasc Surg, 2012, 143(3): 607-12.
  • 8Maeyashiki T, Suzuki K, Hattori A, et al. The size of consolidation on thin-section computed tomographyis a better predictor of survival than the maximum tumourdimension in resectable lung cancer[J]. Eur J Cardiothorac Surg, 2013, 43(5): 915-8.
  • 9Edge SB, Byrd DR, Compton CC, et al. Cancer Staging Manual 7th Ed[M]. New York: Springer, 2010: 253-70.
  • 10Goldstraw P. Staging manual in thoracic oncology[M]. Orange Park, FL: Editorial Rx Press, 2009: 32-3.

共引文献194

同被引文献25

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部